

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response in hours
Employees/employee representatives/or employers.	HHE Request Form	250	1	12/60
Employees	HHE specific interview example †	1,470	1	15/60
Employees	HHE specific questionnaire example †	2,100	1	30/60
Employees	HHE specific medical survey informed consent form.	60	1	30/60
Employees	Employee Contact Postcard	1,225	1	5/60
Employer & employee representative	Initial Site Visit Followback Survey form	140	1	10/60
Employer & employee representative	Closeout for HHE Followback Survey with site visit.	140	1	20/60
Employer & employee representative	1 Year Later for HHE Followback Survey with site visit.	140	1	15/60
Employer & employee representative	Closeout for HHE without site visit	94	1	10/60
Employer & employee representative	1 Year Later for HHE without site visit	94	1	15/60

Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2026–20905 Filed 10–13–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Statement of Delegation of Authority

Notice is hereby given that I have delegated to the Administrator, Centers for Medicare & Medicaid Services (CMS), the authorities vested in the Secretary of Health and Human Services under section 1128(b) of the Social Security Act. This delegation revises the limitations from the March 14, 2011, delegation of authority (76 FR 13618), which superseded the September 6, 1984, DOA as to Section F.50.—Limitations of Authority, subsection (1)(c).

CMS requested that the permissive exclusion authority under Section 1128(b) of the SSA be formally delegated to the CMS Administrator. As the agency directly responsible for administering Medicare and Medicaid, CMS is uniquely positioned to investigate, identify, and develop the evidentiary basis underpinning permissive exclusion determinations. Formalizing this delegation aligns investigative and enforcement responsibilities within a single operating division, reducing redundancy and improving program integrity outcomes.

This delegation will be exercised in accordance with the Department's

applicable policies, procedures, guidelines, and regulations. These authorities may be redelegated. Excluded from this delegation is the authority to conduct hearings and to issue regulations. This delegation does not affect or diminish the Secretary's previous delegation of these authorities to the Inspector General of the Department of Health and Human Services under 53 FR 12993 (Apr. 20, 1988), nor does it affect any actions taken pursuant to that earlier delegation.

All redelegations and edits to this authority are required to be reviewed by the Division of Performance and Organizational Programs, Office of Human Capital, CMS, or its successor. Exercise of this authority is in accordance with established policies, procedures, guidelines, and regulations as prescribed by the Secretary. The Secretary retains the authority to submit reports to Congress and promulgate regulations.

This delegation is effective immediately. I affirm and ratify any actions taken by the Administrator or subordinates that involve the exercise of the authorities delegated therein prior to the effective date of the delegation.

Robert F. Kennedy, Jr.,

Secretary.

[FR Doc. 2026–21001 Filed 10–13–26; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–6739]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Requirements for Cosmetic Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by November 13, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0599. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD